
    
      The duration of study for each patient will include 4-week screening phase prior to first
      inclusion of study drug, 21-day study treatment cycles, end of treatment visit and follow-up
      phase. Each patient will be treated until disease progression, unacceptable toxicity or other
      study discontinuation criteria.
    
  